A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease (FLOW, NCT03819153) is currently recruiting, and its primary endpoint is a composite outcome defined as persistent eGFR decline of greater than or equal to 50%, reaching ESKD, death from kidney disease or death from CV disease
In research models, the combined pathway activation is prized for its exceptional breadth across glucose, appetite, and energy metabolism
The recipes in this guide prioritize fiber alongside protein for exactly this reason
The final analytic sample included 69 participants (55 females and 14 males), as one subject with incomplete survey responses was excluded
How is oral semaglutide different from injectable GLP-1 medications
[59:47] And all of a sudden it's like well, that's kind of autism, right